Cargando…
Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma
Glioblastoma (GBM) is the most common malignant tumor of the central nervous system with poor prognosis. Although the field of immunotherapy in glioma is developing rapidly, glioblastoma is still prone to recurrence under strong immune intervention. The major challenges in the process of immunothera...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656432/ https://www.ncbi.nlm.nih.gov/pubmed/34899760 http://dx.doi.org/10.3389/fimmu.2021.790674 |
_version_ | 1784612280379375616 |
---|---|
author | Li, Yan Ma, Yiqi Wu, Zijun Xie, Ruoxi Zeng, Fanxin Cai, Huawei Lui, Su Song, Bin Chen, Lei Wu, Min |
author_facet | Li, Yan Ma, Yiqi Wu, Zijun Xie, Ruoxi Zeng, Fanxin Cai, Huawei Lui, Su Song, Bin Chen, Lei Wu, Min |
author_sort | Li, Yan |
collection | PubMed |
description | Glioblastoma (GBM) is the most common malignant tumor of the central nervous system with poor prognosis. Although the field of immunotherapy in glioma is developing rapidly, glioblastoma is still prone to recurrence under strong immune intervention. The major challenges in the process of immunotherapy are evaluating the curative effect, accurately distinguishing between treatment-related reactions and tumor recurrence, and providing guidance for clinical decision-making. Since the conventional magnetic resonance imaging (MRI) is usually difficult to distinguish between pseudoprogression and the true tumor progression, many studies have used various advanced imaging techniques to evaluate treatment-related responses. Meanwhile, criteria for efficacy evaluation of immunotherapy are constantly updated and improved. A standard imaging scheme to evaluate immunotherapeutic response will benefit patients finally. This review mainly summarizes the application status and future trend of several advanced imaging techniques in evaluating the efficacy of GBM immunotherapy. |
format | Online Article Text |
id | pubmed-8656432 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86564322021-12-10 Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma Li, Yan Ma, Yiqi Wu, Zijun Xie, Ruoxi Zeng, Fanxin Cai, Huawei Lui, Su Song, Bin Chen, Lei Wu, Min Front Immunol Immunology Glioblastoma (GBM) is the most common malignant tumor of the central nervous system with poor prognosis. Although the field of immunotherapy in glioma is developing rapidly, glioblastoma is still prone to recurrence under strong immune intervention. The major challenges in the process of immunotherapy are evaluating the curative effect, accurately distinguishing between treatment-related reactions and tumor recurrence, and providing guidance for clinical decision-making. Since the conventional magnetic resonance imaging (MRI) is usually difficult to distinguish between pseudoprogression and the true tumor progression, many studies have used various advanced imaging techniques to evaluate treatment-related responses. Meanwhile, criteria for efficacy evaluation of immunotherapy are constantly updated and improved. A standard imaging scheme to evaluate immunotherapeutic response will benefit patients finally. This review mainly summarizes the application status and future trend of several advanced imaging techniques in evaluating the efficacy of GBM immunotherapy. Frontiers Media S.A. 2021-11-25 /pmc/articles/PMC8656432/ /pubmed/34899760 http://dx.doi.org/10.3389/fimmu.2021.790674 Text en Copyright © 2021 Li, Ma, Wu, Xie, Zeng, Cai, Lui, Song, Chen and Wu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Li, Yan Ma, Yiqi Wu, Zijun Xie, Ruoxi Zeng, Fanxin Cai, Huawei Lui, Su Song, Bin Chen, Lei Wu, Min Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma |
title | Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma |
title_full | Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma |
title_fullStr | Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma |
title_full_unstemmed | Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma |
title_short | Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma |
title_sort | advanced imaging techniques for differentiating pseudoprogression and tumor recurrence after immunotherapy for glioblastoma |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656432/ https://www.ncbi.nlm.nih.gov/pubmed/34899760 http://dx.doi.org/10.3389/fimmu.2021.790674 |
work_keys_str_mv | AT liyan advancedimagingtechniquesfordifferentiatingpseudoprogressionandtumorrecurrenceafterimmunotherapyforglioblastoma AT mayiqi advancedimagingtechniquesfordifferentiatingpseudoprogressionandtumorrecurrenceafterimmunotherapyforglioblastoma AT wuzijun advancedimagingtechniquesfordifferentiatingpseudoprogressionandtumorrecurrenceafterimmunotherapyforglioblastoma AT xieruoxi advancedimagingtechniquesfordifferentiatingpseudoprogressionandtumorrecurrenceafterimmunotherapyforglioblastoma AT zengfanxin advancedimagingtechniquesfordifferentiatingpseudoprogressionandtumorrecurrenceafterimmunotherapyforglioblastoma AT caihuawei advancedimagingtechniquesfordifferentiatingpseudoprogressionandtumorrecurrenceafterimmunotherapyforglioblastoma AT luisu advancedimagingtechniquesfordifferentiatingpseudoprogressionandtumorrecurrenceafterimmunotherapyforglioblastoma AT songbin advancedimagingtechniquesfordifferentiatingpseudoprogressionandtumorrecurrenceafterimmunotherapyforglioblastoma AT chenlei advancedimagingtechniquesfordifferentiatingpseudoprogressionandtumorrecurrenceafterimmunotherapyforglioblastoma AT wumin advancedimagingtechniquesfordifferentiatingpseudoprogressionandtumorrecurrenceafterimmunotherapyforglioblastoma |